AR064154A1 - Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas - Google Patents
Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticasInfo
- Publication number
- AR064154A1 AR064154A1 ARP070105448A ARP070105448A AR064154A1 AR 064154 A1 AR064154 A1 AR 064154A1 AR P070105448 A ARP070105448 A AR P070105448A AR P070105448 A ARP070105448 A AR P070105448A AR 064154 A1 AR064154 A1 AR 064154A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr14r15
- nr10r11
- alkyl
- nr12c
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Estos compuestos son utiles para modular la actividad de las quinasas lipídicas, incluyendo PI3K, y para tratar trastornos tales como cáncer mediados por las quinasas lipídicas. Se revelan composiciones farmacéuticas y uso del compuesto para preparar medicamentos. Reivindicacion 1: Un compuesto seleccionado de la formula 1c y la formula 1d, y sus estereoisomeros, isomeros geométricos, tautomeros, solvatos, metabolitos y sales aceptables desde el punto de vista farmacéutico, en los cuales: X es O o S; R1 se selecciona de H, F, CI, Br, I, -C(alquil C1-6)2NR10R11, -(CR14R15)tNR10R11, -C(R14R15)nNR12C(=Y)R10, -(CR14R15)nNR12S(O)2R10, -CH(OR10)R10, -(CR14R15)nOR10, -(CR14R15)nS(O)2R10, -(CR14R15)nS(O)2NR10R11, -C(=Y)R10, - C(=Y)OR10, -C(=Y)NR10R11, -C(=Y)NR12OR10, -C(=O)NR12S(O)2R10, -C(=O)NR12(CR14R15)mNR10R11, -NO2, -NHR12, -NR12C(=Y)R11, -NR12C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12S(O)2R10, -NR12SO2NR10R11, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1- 12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20; R2 se selecciona de H, F, CI, Br, I, arilo C6-20, heteroarilo C1-20, alquilo C1-6, alquenilo C2-8 y alquinilo C2-8; R3 es un grupo heteroarilo monocíclico seleccionado de piridilo, isoxazolilo, imidazolilo, pirazolilo, pirrolilo, tiazolilo, piridazinilo, pirimidinilo, pirazinilo, oxazolilo, furanilo, tienilo, triazolilo, tetrazolilo, donde el grupo heteroarilo monociclico está sustituido en forma opcional con uno o más grupos seleccionados de F, CI, Br, I, -CN, -NR10R11, -OR10, -C(O)R10, -NR10C(O)R11, -N(C(O)R11)2, -NR10C(O)NR10R11, -C(=O)OR10, -C(=O)NR10R11, alquilo C1-C12, y alquil C1-12-OR10; R10, R11 y R12 son en forma independiente H, alquilo C1-C12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20, o R10 y R11 junto con el nitrogeno al cual están unidos en forma opcional forman un anillo heterocíclico C3-20 que contiene en forma opcional uno o más átomos adicionales en el anillo seleccionados de N, O o S, donde dicho anillo heterocíclico está sustituido en forma opcional con uno o más grupos seleccionados en forma independiente de oxo, (CH2)nOR10, NR10R11, CF3, F, CI, Br, I, SO2R10, C(=O)R10, NR12C(=Y)R11, C(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20; R14 y R15 se seleccionan en forma independiente de H, alquilo C1-12 o -(CH2)n-arilo, o R14 y R15 junto con los átomos a los cuales están unidos forman un anillo carbocíclico C3-12 saturado o parcialmente insaturado, mor es un grupo morfolino sustituido en forma opcional con uno o más grupos seleccionados de F, CI, Br, I, -C(alquil C1-6)2NR10R11, -(CR14R15)tNR10R11, -C(R14R15)nNR12C(=Y)R10, -(CR14R15)nNR12S(O)2R10, -CH(OR10)R10, -(CR14R15)nOR10, -(CR14R15)nS(O)2R10, -(CR14R15)nS(O)2NR10R11, -C(=Y)R10, -C(=Y)OR10, - C(=Y)NR10R11, -C(=Y)NR12OR10, -C(=O)NR12S(O)2R10, -C(=O)NR12(CR14R15)mNR10R11, -NO2, -NHR12, -NR12C(=Y)R11, -NR12C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12S(O)2R10, -NR12SO2NR10R11, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20; donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo y heteroarilo están sustituidos en forma opcional con uno o más grupos seleccionados en forma independiente de F, CI, Br, I, -CN, CF3, -NO2, oxo,-C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -(CR14R15)nNR10R11, -(CR14R15)nNR12SO2R10, -(CR14R15)nOR10, -NR10R11, -NR12C(=Y)R10, -NR12C(=Y)OR11, -NR12C(=Y)NR10R11, - NR12SO2R10, =NR12, OR10, OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), SR10, -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, SC(=Y)OR10, -SC(=Y)NR10R11, alquilo C1-12 sustituido en forma opcional, alquenilo C2-8 sustituido en forma opcional, alquinilo C2-8 sustituido en forma opcional, carbociclilo C3-12 sustituido en forma opcional, heterociclilo C2-20 sustituido en forma opcional, arilo C6-20 sustituido en forma opcional, y heteroarilo C1-20 sustituido en forma opcional; Y es O, S o NR12; m es 0, 1, 2, 3, 4, 5 o 6; n es 1, 2, 3, 4, 5 o 6; y t es 2, 3, 4, 5 o 6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87342206P | 2006-12-07 | 2006-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064154A1 true AR064154A1 (es) | 2009-03-18 |
Family
ID=39403189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105448A AR064154A1 (es) | 2006-12-07 | 2007-12-05 | Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas |
Country Status (19)
Country | Link |
---|---|
US (1) | US9487533B2 (es) |
EP (1) | EP2114950B1 (es) |
JP (1) | JP5500990B2 (es) |
KR (1) | KR101507182B1 (es) |
CN (1) | CN101675053B (es) |
AR (1) | AR064154A1 (es) |
AU (1) | AU2007333243B2 (es) |
BR (1) | BRPI0717907A2 (es) |
CA (1) | CA2671845C (es) |
CL (1) | CL2007003523A1 (es) |
ES (1) | ES2571028T3 (es) |
IL (1) | IL199151A (es) |
MX (1) | MX2009005925A (es) |
NO (1) | NO342697B1 (es) |
PE (1) | PE20081353A1 (es) |
RU (1) | RU2470936C2 (es) |
TW (1) | TW200829594A (es) |
WO (1) | WO2008073785A2 (es) |
ZA (1) | ZA200904531B (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1679668B1 (en) * | 1996-09-04 | 2010-01-27 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management |
NZ578162A (en) | 2006-12-07 | 2011-12-22 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
JP5539190B2 (ja) * | 2007-06-12 | 2014-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾロピリミジン類及びホスファチジルイノシトール−3キナーゼのインヒビターとしてのそれらの使用 |
AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
CN101932587A (zh) * | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
CN101909631B (zh) | 2007-10-25 | 2012-09-12 | 健泰科生物技术公司 | 制备噻吩并嘧啶化合物的方法 |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
RU2473549C2 (ru) * | 2008-07-31 | 2013-01-27 | Дженентек, Инк. | Пиримидиновые соединения, композиции и способы применения |
EP2341052A4 (en) * | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
JP2012505836A (ja) | 2008-10-17 | 2012-03-08 | アカール ファーマ ピーティーワイ リミテッド | S1p受容体モジュレーターおよびそれらの使用 |
WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
DK2385832T3 (en) * | 2009-01-08 | 2015-09-21 | Curis Inc | Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用 |
ES2665277T3 (es) * | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
US8785651B2 (en) | 2009-03-24 | 2014-07-22 | Sumitomo Chemical Company, Limited | Method for manufacturing a boronic acid ester compound |
SG182247A1 (en) * | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
CA2761445A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
CA2766151A1 (en) * | 2009-06-24 | 2010-12-29 | Genentech, Inc. | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
CN102762574B (zh) | 2009-09-28 | 2015-12-02 | 霍夫曼-拉罗奇有限公司 | 苯并氧杂*pi3k抑制剂化合物和使用方法 |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
AP2012006294A0 (en) | 2009-11-05 | 2012-06-30 | Rhizen Pharmaceuticals Sa | Novel kinase modulators. |
CN102712642B (zh) * | 2009-11-12 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法 |
BR112012011188A2 (pt) * | 2009-11-12 | 2021-06-29 | F.Hoffmann - La Roche Ag | ''composto,composição farmacêutica e uso de um composto" |
EP2539337A1 (en) | 2010-02-22 | 2013-01-02 | F. Hoffmann-La Roche AG | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス,インコーポレイテッド | K−ras変異を有する癌の治療 |
SG186378A1 (en) | 2010-06-23 | 2013-01-30 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
WO2012007493A1 (en) | 2010-07-14 | 2012-01-19 | F. Hoffmann-La Roche Ag | Purine compounds selective for ρi3κ p110 delta, and methods of use |
DE102010049595A1 (de) * | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
TW201500358A (zh) | 2010-12-16 | 2015-01-01 | Hoffmann La Roche | 三環pi3k抑制劑化合物及其使用方法 |
EA201300867A1 (ru) * | 2011-01-27 | 2014-03-31 | Дзе Трастиз Оф Принстон Юнивесити | ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ |
KR20130116358A (ko) | 2011-02-09 | 2013-10-23 | 에프. 호프만-라 로슈 아게 | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 |
EP2683243A4 (en) * | 2011-03-09 | 2014-12-03 | Celgene Avilomics Res Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
US9090628B2 (en) | 2011-03-21 | 2015-07-28 | Genentech, Inc. | Benzoxazepin compounds selective for PI3K P110 delta and methods of use |
SG10201602569RA (en) | 2011-04-01 | 2016-05-30 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
SI3330257T1 (sl) | 2011-04-08 | 2020-07-31 | Janssen Sciences Ireland Unlimited Company | Derivati pirimidina za zdravljenje virusnih okužb |
WO2012151525A1 (en) | 2011-05-04 | 2012-11-08 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinases |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
ES2690082T3 (es) | 2011-11-09 | 2018-11-19 | Janssen Sciences Ireland Uc | Derivados de purina para el tratamiento de infecciones virales |
CA2855446C (en) * | 2011-11-23 | 2021-04-20 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase c |
JP6077642B2 (ja) | 2012-04-10 | 2017-02-08 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用 |
KR101761464B1 (ko) | 2012-05-23 | 2017-07-25 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
EP3545968A1 (en) | 2012-06-08 | 2019-10-02 | F. Hoffmann-La Roche AG | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
SI2870157T1 (en) * | 2012-07-04 | 2018-02-28 | Rhizen Pharmaceuticals S.A. | SELECTIVE PI3K-DELTA INHIBITORS |
MX360718B (es) | 2012-07-13 | 2018-11-13 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para el tratamiento de infecciones víricas. |
ES2594078T3 (es) * | 2012-10-10 | 2016-12-15 | F. Hoffmann-La Roche Ag | Proceso para preparar compuestos de tienopirimidina |
US9499549B2 (en) | 2012-10-10 | 2016-11-22 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
JP6297055B2 (ja) | 2012-11-16 | 2018-03-20 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体 |
KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
JP6336036B2 (ja) | 2013-03-29 | 2018-06-06 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染治療のための大環状デアザプリノン |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
SG11201509520QA (en) | 2013-05-24 | 2015-12-30 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
WO2014207082A1 (en) | 2013-06-27 | 2014-12-31 | Janssen R&D Ireland | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
MY179503A (en) * | 2013-07-30 | 2020-11-09 | Janssen Sciences Ireland Uc | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
CN104513254B (zh) | 2013-09-30 | 2019-07-26 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2015190316A1 (ja) * | 2014-06-09 | 2015-12-17 | 住友化学株式会社 | ピリジン化合物の製造方法 |
TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
KR20160082062A (ko) | 2014-12-30 | 2016-07-08 | 한미약품 주식회사 | 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체 |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
MX2017016346A (es) | 2015-06-29 | 2018-05-02 | Hoffmann La Roche | Metodos de tratamiento con taselisib. |
CN106467545B (zh) * | 2015-08-20 | 2018-10-16 | 北大方正集团有限公司 | 一种噻吩并嘧啶化合物 |
SG11201804901WA (en) * | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
WO2018001952A1 (en) * | 2016-06-29 | 2018-01-04 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection |
JP7171444B2 (ja) | 2016-07-01 | 2022-11-15 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染治療用のジヒドロピラノピリミジン |
CN109790154B (zh) | 2016-09-29 | 2023-06-23 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的嘧啶前药 |
EP3573992B1 (en) | 2017-01-26 | 2022-04-13 | Youla S. Tsantrizos | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof |
CN107163061A (zh) * | 2017-04-14 | 2017-09-15 | 江西科技师范大学 | 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用 |
US10588894B2 (en) | 2017-06-21 | 2020-03-17 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
US11234986B2 (en) | 2018-09-11 | 2022-02-01 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
CN109540859B (zh) * | 2018-11-27 | 2021-02-09 | 上海交通大学 | 一种水体中抗生素的分析和含量预测方法 |
CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
WO2022152229A1 (zh) * | 2021-01-15 | 2022-07-21 | 深圳微芯生物科技股份有限公司 | 一类吗啉衍生物及其制备方法和应用 |
CN116262758A (zh) * | 2021-12-15 | 2023-06-16 | 上海博悦生物科技有限公司 | 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途 |
CN114539293B (zh) * | 2022-02-24 | 2023-09-22 | 广东晨康生物科技有限公司 | 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
DE2050814A1 (de) | 1970-10-16 | 1972-04-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen |
DE1959403A1 (de) | 1969-11-26 | 1971-06-03 | Thomae Gmbh Dr K | Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
DE2058085A1 (de) * | 1970-11-26 | 1972-05-31 | Thomae Gmbh Dr K | Neues Verfahren zur Herstellung von 4-Morpholino-thieno[3,2-d]pyrimidinen |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
CH592668A5 (es) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
ZA782648B (en) | 1977-05-23 | 1979-06-27 | Ici Australia Ltd | The prevention,control or eradication of infestations of ixodid ticks |
RU1391052C (ru) * | 1986-08-25 | 1993-11-30 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью |
US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
DE60144322D1 (de) | 2000-04-27 | 2011-05-12 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
WO2002026745A1 (fr) * | 2000-09-29 | 2002-04-04 | Nippon Soda Co., Ltd. | Composes de thienopyrimidine et leurs sels et procede de preparation |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
WO2006004601A1 (en) * | 2004-06-03 | 2006-01-12 | Nordson Corporation | Color change for powder coating material application system |
US7557112B2 (en) | 2004-10-08 | 2009-07-07 | Astellas Pharma Inc. | Aromatic-ring-fused pyrimidine derivative |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
EP2402347A1 (en) | 2006-04-26 | 2012-01-04 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
BRPI0710866A2 (pt) | 2006-04-26 | 2012-08-14 | Hoffmann La Roche | compostos farmacÊuticos |
EP2046799B1 (en) * | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
AU2007246793B2 (en) | 2006-04-26 | 2013-02-07 | F. Hoffmann-La Roche Ag | Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
NZ578162A (en) | 2006-12-07 | 2011-12-22 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
-
2007
- 2007-12-05 KR KR1020097014132A patent/KR101507182B1/ko active IP Right Grant
- 2007-12-05 US US11/951,189 patent/US9487533B2/en active Active
- 2007-12-05 PE PE2007001727A patent/PE20081353A1/es not_active Application Discontinuation
- 2007-12-05 CA CA2671845A patent/CA2671845C/en not_active Expired - Fee Related
- 2007-12-05 WO PCT/US2007/086533 patent/WO2008073785A2/en active Application Filing
- 2007-12-05 AR ARP070105448A patent/AR064154A1/es unknown
- 2007-12-05 AU AU2007333243A patent/AU2007333243B2/en not_active Ceased
- 2007-12-05 TW TW096146408A patent/TW200829594A/zh unknown
- 2007-12-05 ES ES07865255T patent/ES2571028T3/es active Active
- 2007-12-05 CN CN200780051049.8A patent/CN101675053B/zh active Active
- 2007-12-05 JP JP2009540457A patent/JP5500990B2/ja active Active
- 2007-12-05 BR BRPI0717907-3A2A patent/BRPI0717907A2/pt not_active Application Discontinuation
- 2007-12-05 EP EP07865255.9A patent/EP2114950B1/en active Active
- 2007-12-05 RU RU2009125916/04A patent/RU2470936C2/ru not_active IP Right Cessation
- 2007-12-05 MX MX2009005925A patent/MX2009005925A/es active IP Right Grant
- 2007-12-05 CL CL200703523A patent/CL2007003523A1/es unknown
- 2007-12-05 ZA ZA200904531A patent/ZA200904531B/xx unknown
-
2009
- 2009-06-04 IL IL199151A patent/IL199151A/en not_active IP Right Cessation
- 2009-07-06 NO NO20092565A patent/NO342697B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL199151A (en) | 2017-01-31 |
WO2008073785A2 (en) | 2008-06-19 |
KR20090106508A (ko) | 2009-10-09 |
AU2007333243B2 (en) | 2013-03-14 |
EP2114950A2 (en) | 2009-11-11 |
PE20081353A1 (es) | 2008-11-12 |
TW200829594A (en) | 2008-07-16 |
US20080269210A1 (en) | 2008-10-30 |
NO342697B1 (no) | 2018-07-09 |
AU2007333243A1 (en) | 2008-06-19 |
CN101675053A (zh) | 2010-03-17 |
ES2571028T3 (es) | 2016-05-23 |
RU2009125916A (ru) | 2011-01-20 |
ZA200904531B (en) | 2010-09-29 |
RU2470936C2 (ru) | 2012-12-27 |
KR101507182B1 (ko) | 2015-03-30 |
MX2009005925A (es) | 2009-08-12 |
EP2114950B1 (en) | 2016-03-09 |
WO2008073785A3 (en) | 2008-08-28 |
CA2671845C (en) | 2015-03-24 |
CA2671845A1 (en) | 2008-06-19 |
CL2007003523A1 (es) | 2008-08-22 |
CN101675053B (zh) | 2014-03-12 |
BRPI0717907A2 (pt) | 2013-11-05 |
NO20092565L (no) | 2009-09-07 |
US9487533B2 (en) | 2016-11-08 |
JP5500990B2 (ja) | 2014-05-21 |
IL199151A0 (en) | 2010-03-28 |
JP2010512337A (ja) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064154A1 (es) | Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas | |
AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
AR068402A1 (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso | |
HRP20192336T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
AR060632A1 (es) | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso | |
PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
JP2016530262A5 (es) | ||
ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
AR076984A1 (es) | Derivados de pirazol oxadiazol | |
CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
AR077507A1 (es) | Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk | |
AR067093A1 (es) | N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas | |
RU2018112252A (ru) | Конденсированное пиримидиновое соединение или его соль | |
RS54358B1 (en) | PYROLOPYRIDINES AS KINASE INHIBITORS | |
AR078187A1 (es) | Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. | |
MX2020008570A (es) | Inhibidores de arginasa y sus metodos de uso. | |
CO6140024A2 (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer | |
AR079199A1 (es) | Composiciones farmaceuticas que comprenden ligandos de receptores sigma | |
ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
JP2019521097A5 (es) | ||
AR076187A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen | |
AR054625A1 (es) | Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos. | |
RU2015140387A (ru) | Пиридопиримидиновое или пиримидопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений | |
RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
JP2016528245A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |